Pharmacokinetics, safety, efficacy and immunogenicity of Adalimumab biosimilar ABP-501in rheumatoid arthritis and plaque psoriasis
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021.
Príomhchruthaitheoir: | Akter, Anika |
---|---|
Rannpháirtithe: | Alam, Marzia |
Formáid: | Tráchtas |
Teanga: | English |
Foilsithe / Cruthaithe: |
Brac University
2022
|
Ábhair: | |
Rochtain ar líne: | http://hdl.handle.net/10361/17039 |
Míreanna comhchosúla
-
Biologics and Biosimilars as Treatment Options for Psoriasis
de réir: Moya, Amena Khatun
Foilsithe / Cruthaithe: (2023) -
Importance of biologics in rheumatoid arthritis management
de réir: Riyadh, S. M.
Foilsithe / Cruthaithe: (2022) -
TNF-α inhibitor-induced alopecia in psoriatic disease patients: a pharmacovigilance study
de réir: Afroza, Halima
Foilsithe / Cruthaithe: (2024) -
Importance of biologically active agents over other therapies in Rheumatoid Arthritis- a review
de réir: Mehreen, Elnaj
Foilsithe / Cruthaithe: (2021) -
A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
de réir: Islam, Nahidul
Foilsithe / Cruthaithe: (2023)